MA45985A - Inhibiteurs de diacylglycérol acyltransférase 2 - Google Patents

Inhibiteurs de diacylglycérol acyltransférase 2

Info

Publication number
MA45985A
MA45985A MA045985A MA45985A MA45985A MA 45985 A MA45985 A MA 45985A MA 045985 A MA045985 A MA 045985A MA 45985 A MA45985 A MA 45985A MA 45985 A MA45985 A MA 45985A
Authority
MA
Morocco
Prior art keywords
inhibitors
diacylglycerol acyltransferase
acyltransferase
diacylglycerol
dgat2
Prior art date
Application number
MA045985A
Other languages
English (en)
Other versions
MA45985B1 (fr
Inventor
Markus Boehm
Shawn Cabral
Matthew S Dowling
Kentaro Futatsugi
Kim Huard
Esther Cheng Yin Lee
Qifang Li
Allyn T Londregan
Jana Polivkova
David A Price
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA45985A publication Critical patent/MA45985A/fr
Publication of MA45985B1 publication Critical patent/MA45985B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)

Abstract

La présente invention concerne des composés de formule i qui inhibent l'activité de la diacylglycérol acyltransférase 2 (dgat2) et leurs utilisations pour le traitement de maladies liées à celle-ci chez l'animal.
MA45985A 2016-08-19 2017-08-09 Inhibiteurs de diacylglycérol acyltransférase 2 MA45985B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662377137P 2016-08-19 2016-08-19
PCT/IB2017/054862 WO2018033832A1 (fr) 2016-08-19 2017-08-09 Inhibiteurs de diacylglycérol acyltransférase 2

Publications (2)

Publication Number Publication Date
MA45985A true MA45985A (fr) 2019-06-26
MA45985B1 MA45985B1 (fr) 2020-10-28

Family

ID=59762015

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45985A MA45985B1 (fr) 2016-08-19 2017-08-09 Inhibiteurs de diacylglycérol acyltransférase 2

Country Status (44)

Country Link
US (5) US10071992B2 (fr)
EP (1) EP3500564B1 (fr)
JP (1) JP6657473B2 (fr)
KR (1) KR102225925B1 (fr)
CN (1) CN109641875B (fr)
AR (1) AR109179A1 (fr)
AU (1) AU2017313420B2 (fr)
CA (1) CA2976690C (fr)
CL (1) CL2019000406A1 (fr)
CO (1) CO2019001421A2 (fr)
CR (1) CR20190085A (fr)
CU (1) CU24507B1 (fr)
CY (1) CY1123679T1 (fr)
DK (1) DK3500564T3 (fr)
DO (1) DOP2019000032A (fr)
EA (1) EA037476B1 (fr)
EC (1) ECSP19012670A (fr)
ES (1) ES2834060T3 (fr)
GE (1) GEP20207159B (fr)
HR (1) HRP20201748T1 (fr)
HU (1) HUE051731T2 (fr)
IL (1) IL264818B (fr)
LT (1) LT3500564T (fr)
MA (1) MA45985B1 (fr)
MD (1) MD3500564T2 (fr)
MX (1) MX370766B (fr)
MY (1) MY196330A (fr)
NI (1) NI201900012A (fr)
NZ (1) NZ750412A (fr)
PE (1) PE20190518A1 (fr)
PH (1) PH12019500349B1 (fr)
PL (1) PL3500564T3 (fr)
PT (1) PT3500564T (fr)
RS (1) RS61141B1 (fr)
RU (1) RU2719589C1 (fr)
SG (1) SG11201900490WA (fr)
SI (1) SI3500564T1 (fr)
SV (1) SV2019005823A (fr)
TN (1) TN2019000036A1 (fr)
TW (1) TWI688560B (fr)
UA (1) UA122100C2 (fr)
UY (1) UY37366A (fr)
WO (1) WO2018033832A1 (fr)
ZA (1) ZA201900516B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR109179A1 (es) * 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN112074286A (zh) 2018-01-23 2020-12-11 吉拉毒蜥治疗公司 肽yy药物制剂、组合物和方法
WO2019175869A1 (fr) 2018-03-12 2019-09-19 Yeda Research And Development Co. Ltd Traitement d'une maladie cardiaque
CA3045644C (fr) 2018-06-13 2024-01-16 Pfizer Inc. Antagonistes du recepteur glp-1 et leurs utilisations
AU2019329884B2 (en) 2018-08-31 2022-01-27 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
RU2706026C1 (ru) * 2018-12-28 2019-11-13 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы Способ лечения неалкогольной жировой болезни печени и сахарного диабета второго типа
EP3972596B1 (fr) 2019-05-20 2025-07-16 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
WO2021076817A2 (fr) * 2019-10-16 2021-04-22 Ohio State Innovation Foundation Procédés et compositions associés au traitement et à la prévention du cancer par inhibition de dgat1 et dgat2
US20230045419A1 (en) 2019-12-10 2023-02-09 Pfizer Inc. Solid Forms of 2-((4-((S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt
BR112022012352A2 (pt) * 2019-12-23 2022-09-06 Lg Chemical Ltd Novo derivado de amida útil como inibidor de diacilglicerol aciltransferase 2 e uso do mesmo
WO2021133035A1 (fr) * 2019-12-23 2021-07-01 주식회사 엘지화학 Nouveau dérivé amino-aryle utile en tant qu'inhibiteur de diacylglycérol acyltransférase 2 et son utilisation
DK4097099T3 (da) 2020-02-07 2024-07-15 Gasherbrum Bio Inc Heterocyckliske GLP1-agonister
WO2021161222A1 (fr) * 2020-02-11 2021-08-19 Inorbit Therapeutics Ab Composés utiles pour inhiber la diacylglycérol o-acyltransférase et leurs procédés de fabrication et d'utilisation
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) * 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
BR112022017578A2 (pt) 2020-03-27 2022-10-18 Pfizer Tratamento do diabetes tipo 2 ou obesidade ou sobrepeso com ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico ou um sal farmacêutico do mesmo
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
EP4153596A4 (fr) 2020-05-18 2024-08-14 Merck Sharp & Dohme LLC Nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2
LT4161927T (lt) 2020-06-09 2024-09-25 Pfizer Inc. Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas
TWI817191B (zh) * 2020-09-04 2023-10-01 南韓商Ｌｇ化學股份有限公司 新穎聯芳基衍生物及其作為針對二醯基甘油醯基轉移酶２之抑制劑之用途
MX2023003842A (es) 2020-10-08 2023-04-14 Merck Sharp & Dohme Llc Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2.
KR20230079427A (ko) 2020-10-08 2023-06-07 머크 샤프 앤드 돔 엘엘씨 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 옥스인돌 유도체의 제조
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112972654B (zh) * 2021-03-05 2022-07-01 温州医科大学慈溪生物医药研究院 Fgf21在制备治疗脑神经损伤的药物中的应用
US20250066337A1 (en) 2021-08-26 2025-02-27 Pfizer Inc. Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide
US20250129057A1 (en) 2021-08-31 2025-04-24 Pfizer Inc. Solid Forms of 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt
IL312296A (en) * 2021-12-01 2024-06-01 Pfizer 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART
ES3039638T3 (en) 2021-12-06 2025-10-23 Pfizer Melanocortin 4 receptor antagonists and uses thereof
US20250188103A1 (en) 2022-03-09 2025-06-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2025513071A (ja) 2022-04-14 2025-04-22 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
WO2023228023A1 (fr) 2022-05-23 2023-11-30 Pfizer Inc. Traitement du diabète de type 2 ou contrôle de la gestion du poids avec de l'acide 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-benzo[d]imidazole-6-carboxylique ou un sel pharmaceutique de celui-ci
CN115089590B (zh) * 2022-06-13 2023-05-12 同济大学 环戊基三唑嘧啶类药物作为药物成分在肝炎药物中的应用
WO2024118858A1 (fr) 2022-12-02 2024-06-06 Merck Sharp & Dohme Llc Préparation de dérivés d'azole fusionnés utilisés en tant que nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2
CN121002014A (zh) 2022-12-15 2025-11-21 加舒布鲁姆生物公司 具有glp-1激动剂活性的化合物的盐和固体形式
KR20250172881A (ko) 2023-04-14 2025-12-09 화이자 인코포레이티드 글루코스-의존성 인슐린 분비 촉진 폴리펩티드 수용체 길항제 및 이의 용도
WO2025099561A1 (fr) 2023-11-07 2025-05-15 Pfizer Inc. Formulations de matrice à libération contrôlée orales d'acide 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}pipéridin-1-yl)méthyl]-1-[(2s)-oxétan-2-ylméthyl]-1h-benzimidazole-6-carboxylique ou d'un sel pharmaceutiquement acceptable de celui-ci
WO2025141495A1 (fr) 2023-12-28 2025-07-03 Pfizer Inc. Nouveau procédé de préparation d'ervogastat
WO2025163561A1 (fr) 2024-02-01 2025-08-07 Pfizer Inc. Antagonistes du récepteur du polypeptide insulinotrope dépendant du glucose et leurs utilisations
US20250326741A1 (en) 2024-04-22 2025-10-23 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2025224648A1 (fr) 2024-04-26 2025-10-30 Pfizer Inc. Compositions/formulations orales de l'acide 2-({4-[(2s)-2-(4-chloro-2-fluorophényl)-2-méthyl-1,3-benzodioxol-4-yl]pipéridin-1-yl}méthyl)-1-[(2s)-oxétan-2-ylméthyl]-1h-benzimidazole-6-carboxylique ou d'un sel pharmaceutiquement acceptable de celui-ci

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (fr) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
EP0580860B2 (fr) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Procede de production d'une dispersion solide
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
CN1149196C (zh) 1998-07-06 2004-05-12 布里斯托尔-迈尔斯斯奎布公司 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EA200300944A1 (ru) 2001-02-28 2004-04-29 Мерк Энд Ко., Инк. Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
HRP20040716A2 (en) 2002-02-27 2005-02-28 Pfizer Products Inc. Acc inhibitors
HRP20090471T1 (hr) 2004-05-12 2009-10-31 Pfizer Products Inc. Derivati prolina i njihova upotreba kao inhibitori dipeptidil-peptidaze iv
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EP2463283B1 (fr) 2006-04-20 2014-06-11 Pfizer Products Inc. Composés phényle amido-hétérocycliques fusionnés pour la prévention et le traitement de maladies à médiation par glucokinase
CN101541809A (zh) 2006-11-29 2009-09-23 辉瑞产品公司 螺环酮乙酰基-CoA羧化酶抑制剂
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
CA2707660A1 (fr) * 2007-12-20 2009-07-02 Astrazeneca Ab Composes carbamoyles comme inhibiteurs de dgat1 190
EP2297164A1 (fr) 2008-05-28 2011-03-23 Pfizer Inc. Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
MX2011002166A (es) 2008-08-28 2011-04-07 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
CA2745445A1 (fr) 2008-12-17 2010-07-08 Via Pharmaceuticals, Inc. Inhibiteurs de la diacylglycerol acyltransferase
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
JP5086480B2 (ja) 2009-03-11 2012-11-28 ファイザー・インク グルコキナーゼ活性化剤として使用されるベンゾフラニル誘導体
CA2754685A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Indazole amides substitues
US20120095028A1 (en) 2009-03-20 2012-04-19 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
WO2010128414A1 (fr) 2009-05-08 2010-11-11 Pfizer Inc. Modulateurs du gpr119
CA2759843A1 (fr) 2009-05-08 2010-11-10 Pfizer Inc. Modulateurs de gpr119
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
CA2852609C (fr) * 2011-11-29 2020-03-10 F. Hoffmann-La Roche Ag Derives aminopyridines en tant que modulateurs de lrrk2
WO2013137628A1 (fr) 2012-03-16 2013-09-19 한국생명공학연구원 Nouvelle matière d'inhibition de diacylglycérol acyltransférase-2, et son utilisation
US9296745B2 (en) 2012-04-06 2016-03-29 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
CA2903285C (fr) * 2013-03-15 2021-05-11 Deciphera Pharmaceuticals, Llc 2-aminopyrimidin-6-ones et analogues montrant des activites anticancereuses et antiproliferatives
AR098394A1 (es) 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
KR101772836B1 (ko) * 2014-03-17 2017-08-29 화이자 인코포레이티드 대사 및 관련 장애의 치료에 사용하기 위한 디아실글리세롤 아실트랜스퍼라제 2 억제제
EP3188730B1 (fr) 2014-09-05 2019-05-01 Merck Sharp & Dohme Corp. Dérivés de tétrahydroisoquinoléine utiles en tant qu'inhibiteurs de diacylglycéride o-acyltransférase 2
EP3188732B1 (fr) 2014-09-05 2019-07-24 Merck Sharp & Dohme Corp. Dérivés de tétrahydroisoquinoléine utiles en tant qu'inhibiteurs de diacylglycéride o-acyltransférase 2
US9828369B2 (en) 2014-09-05 2017-11-28 Merck Sharpe & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
AR109179A1 (es) * 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
US10017992B2 (en) 2016-11-04 2018-07-10 Ashmin Holding Llc Radial ball bearing and method

Also Published As

Publication number Publication date
HRP20201748T1 (hr) 2020-12-25
LT3500564T (lt) 2020-12-28
US11034678B2 (en) 2021-06-15
AR109179A1 (es) 2018-11-07
US11866425B2 (en) 2024-01-09
MX2019001872A (es) 2019-06-13
ZA201900516B (en) 2019-10-30
IL264818B (en) 2021-05-31
PH12019500349A1 (en) 2019-12-16
EA201990202A1 (ru) 2019-07-31
MD3500564T2 (ro) 2020-12-31
SV2019005823A (es) 2019-03-19
RS61141B1 (sr) 2020-12-31
ES2834060T3 (es) 2021-06-16
EP3500564B1 (fr) 2020-10-07
CL2019000406A1 (es) 2019-07-05
UA122100C2 (uk) 2020-09-10
ECSP19012670A (es) 2019-03-29
CU24507B1 (es) 2021-04-07
SG11201900490WA (en) 2019-03-28
NZ750412A (en) 2025-08-29
CY1123679T1 (el) 2022-03-24
CA2976690C (fr) 2025-01-07
TW201819366A (zh) 2018-06-01
CN109641875A (zh) 2019-04-16
MX370766B (es) 2019-12-17
PE20190518A1 (es) 2019-04-10
BR112019001976A2 (pt) 2019-05-07
SI3500564T1 (sl) 2021-01-29
PL3500564T3 (pl) 2021-04-06
US10071992B2 (en) 2018-09-11
CO2019001421A2 (es) 2019-03-08
RU2719589C1 (ru) 2020-04-21
US20210309646A1 (en) 2021-10-07
CN109641875B (zh) 2021-08-31
AU2017313420B2 (en) 2020-12-24
JP6657473B2 (ja) 2020-03-04
US20180051012A1 (en) 2018-02-22
MA45985B1 (fr) 2020-10-28
WO2018033832A1 (fr) 2018-02-22
KR20190035897A (ko) 2019-04-03
EA037476B1 (ru) 2021-04-01
CR20190085A (es) 2019-05-09
MY196330A (en) 2023-03-24
EP3500564A1 (fr) 2019-06-26
KR102225925B1 (ko) 2021-03-09
CU20190003A7 (es) 2019-09-04
JP2019524831A (ja) 2019-09-05
US20180258081A1 (en) 2018-09-13
TWI688560B (zh) 2020-03-21
DK3500564T3 (da) 2020-10-19
UY37366A (es) 2018-03-23
US20200181127A1 (en) 2020-06-11
NI201900012A (es) 2019-04-08
PH12019500349B1 (en) 2023-03-24
US20240140937A1 (en) 2024-05-02
DOP2019000032A (es) 2019-04-15
TN2019000036A1 (en) 2020-07-15
PT3500564T (pt) 2020-11-25
GEP20207159B (en) 2020-10-12
HUE051731T2 (hu) 2021-03-29
AU2017313420A1 (en) 2019-02-07
CA2976690A1 (fr) 2018-02-19

Similar Documents

Publication Publication Date Title
MA45985A (fr) Inhibiteurs de diacylglycérol acyltransférase 2
MA39753B1 (fr) Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
MA38483A1 (fr) Inhibiteurs de l'ido
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MA54386B1 (fr) Modulateurs de trex1
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
EP2563794A4 (fr) Inhibiteurs de l'activité protéine tyrosine kinase et leurs applications au traitement de troubles ophtalmiques
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
ZA201901168B (en) Novel compounds for treating parasitic disease
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
EP4021858A4 (fr) Traitement d'azoles
MA39260A1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
MA42681B1 (fr) Inhibiteurs de l'ezh2
MA39719B1 (fr) Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA38473B1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c